Immobilized HHLA2 Protein, Human, Recombinant (His Tag) at 2 μg/mL (100 μL/well) can bind CD28H/TMIGD2 Protein, Human, Recombinant (ECD, hFc Tag), the EC50 is 140-420 ng/mL.

HHLA2 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 38.4 kDa and the accession number is Q9UM44-1.

Human

HEK293 Cells

HERV-H LTR-associating 2,HHLA2,B7-H7,B7H7

The Human HHLA2 (NP_009003.1) (Met1-Asn344) was expressed with a polyhistidine tag at the C-terminus.

≥ 95 % as determined by SDS-PAGE. ≥ 95 % as determined by SEC-HPLC.

A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

B7H7 gene encodes a protein-ligand found on the surface of monocytes. The encoded protein is thought to regulate cell-mediated immunity by binding to a receptor on T lymphocytes and inhibiting the proliferation of these cells. Alternate splicing results in multiple transcript variants. HERV–H LTR-associating 2 (HHLA2, also called B7H7/B7-H5/B7y)has been recently discovered as the newest member of the B7 family and has 23–33% similarity in amino acid sequence with the other B7 molecules. This ligand is the only B7 family member that is found in humans but not in mice. It is constitutively expressed on the surface of human monocytes and is induced on B cells. HHLA2 binds to its putative receptor(s) on a variety of immune cells including CD4 and CD8 T cells and antigen-presenting cells. Similar to B7-H3, both a T cell coinhibitory role, as well as a costimulatory role, has been reported for this ligand.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy